Flemming Winther Bach

Effekten af det syntetiske cannabinoid, dronabinol, på central smerte hos patienter med dissemineret sklerose--sekundaerpublikation

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Cannabinoids reduce allodynia/hyperalgesia in animal pain models, but few clinical studies evaluated the analgesic action in humans. We aimed to evaluate the effect of delta-9-tetrahydrocannabinol (dronabinol) on central pain in MS patients. Twenty-four MS patients participated in a double-blind placebo-controlled crossover trial. Dronabinol reduced the spontaneous pain intensity significantly compared with placebo (4.0 (2.3-6.0) vs. 5.0 (4.0-6.4), median (25th-75th percentiles), p = 0.02). Though dronabinol's analgesic effect is modest, its use should be evaluated considering the general difficulty in treating central pain.
TidsskriftUgeskrift for Laeger
Sider (fra-til)2772-4
Antal sider3
StatusUdgivet - 2005


  • Administration, Oral, Adult, Analgesics, Non-Narcotic, Cross-Over Studies, Double-Blind Method, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Pain, Pain Measurement, Tetrahydrocannabinol, Treatment Outcome

Se relationer på Aarhus Universitet Citationsformater

ID: 52802979